EARN 1.25 CME CREDITS!

TARGET AUDIENCE
This activity is intended for orthopaedic surgeons, pain management specialists, and other physicians who treat patients with chronic pain associated with osteoarthritis (OA).

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
• Review the pathophysiology of OA-related chronic pain, including potential therapeutic targets
• Evaluate patients with OA for persistent pain, functional status, and potential risks related to treatment options
• Discuss the challenges associated with current analgesic modalities for chronic pain in patients with OA
• Compare the clinical profiles of current and emerging treatment options for OA-related chronic pain

PROGRAM DESCRIPTION
Undertreated pain is a national crisis, and healthcare providers are challenged by the growing number of patients with OA-related chronic pain. As a complex, multidimensional experience, OA-related chronic pain is associated with disability, affective symptoms, cognitive impairment, and deconditioning, and is the most common indication for joint replacement surgery. Burdens and risks associated with the most commonly prescribed pharmacologic analgesics for OA-related chronic pain can leave providers at a loss with how to manage some patients. Our growing knowledge of OA pain mechanisms has revealed novel treatment targets; one underappreciated factor in modulating chronic pain development is nerve growth factor (NGF), which contributes to the activation and sensitization of pain receptors and in OA, promotes hyperalgesia during synovial inflammation and cartilage degradation. A multidisciplinary panel for this live Interactive Exchange™ webinar will cover OA pain pathophysiology, comprehensive strategies to assess the multidimensional effects of ongoing pain, the role of the orthopedic surgeon in pain management, and both current and emerging therapeutic options for OA-related chronic pain.

JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
PIM designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF CONFLICTS OF INTEREST
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

Scott A. Rodeo, MD
Consulting fees: Advance Medical; Ownership Interest: Ortho Regenerative Technologies Inc.

Thomas J. Schnitzer, MD, PhD
Consulting fees: Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, GlaxoSmithKline plc; Contracted Research: Pfizer Inc., Eli Lilly and Company, Regeneron Pharmaceuticals, Inc.

PLANNERS AND MANAGERS
The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must receive a minimum score of 75% on the posttest and complete the evaluation.

CME QUESTIONS – PIM CONTACT INFORMATION
For information about the accreditation of this program, please contact PIM via e-mail at inquiries@pimed.com or by visiting www.pimed.com.

INTEGRITAS CONTACT INFORMATION
For all other questions regarding this webinar, please contact Christa Master at cmaster@integritasgrp.com.

FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.

Media:
• Internet
Minimum Hardware/Software Requirements:
• Valid email address
• Broadband internet connection
• Computer, smartphone, or tablet
• Multimedia playback capability, including speakers or headphones
System Requirements:
• Browser: Chrome or Firefox (Up to date)
• Internet: Consistent, high-speed, 10Mbps+
• Firewalls: None that block webinars
• Video Apps: None open (e.g., Skype)

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

This activity is supported by an independent educational grant from Pfizer, Inc. and Eli Lilly and Company.